South Korean biotech ToolGen has won court approval to patent its genome editing technology CRISPR, after an earlier bid to protect its IP found the revolutionary technology was not patentable.
The litigation funder that bankrolled a patent infringement case by a vehicle monitoring systems manufacturer is on the hook for legal costs after technology company SARB succeeded in appealing a finding that it infringed the IP for a parking detection system used by the City of Melbourne.
US animal drug manufacturer Zoetis has been granted leave to appeal a ruling that invalidated three of its patents covering pig vaccines.
Technology company SARB has partially succeeded in a challenge to a ruling that it infringed a rival’s intellectual property in its development of a parking system used by the City of Melbourne, with an appeals court finding a judge made an error in his reading of the claims of one patent at issue.
Novartis unit Sandoz AG has filed an appeal after it was was barred from selling a generic version of top-selling blood clot drug Xarelto and failed to revoke two Bayer patents for the drug.
Novartis unit Sandoz AG has lost its bid to revoke Bayer’s patents for its top-selling blood clot drug Xarelto and has been barred from selling generic versions of the medication after a judge found the German pharma giant’s patents were valid.
Tech company SARB has won a stay of orders barring it from selling its sensor-based system which the city of Melbourne uses for timing parked vehicles, after a judge found it infringed rival Vehicle Management Systems’ patent.
German drug maker Boehringer has prevailed in its Federal Court fight against US rival Zoetis over the validity of three patents covering pig vaccines.
A judge has upheld findings from IP Australia that South Korean biotech ToolGen’s genome editing technology CRISPR is not patentable, but given the company one more chance to seek to amend its application.
Novartis unit Sandoz has won its bid to stay a case by rival Lundbeck, including orders for damages previously calculated at $26.3 million and counting, despite having succeeded at the High Court in a dispute over its patent for blockbuster antidepressant Lexapro.